Company Filing History:
Years Active: 2015-2016
Title: Hyun-Sook Jang: Innovator in Monoclonal Antibody Research
Introduction
Hyun-Sook Jang is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, Jang's work focuses on innovative solutions for cancer treatment.
Latest Patents
One of Jang's latest patents is titled "Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof." This invention relates to human monoclonal antibodies that neutralize vascular endothelial growth factor receptors. Specifically, it involves human ScFv molecules that inhibit angiogenesis and provide compositions for cancer treatment. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies. It has the capability to neutralize vascular endothelial growth factor receptors in humans, mice, and rats, making it a valuable asset in anticancer studies.
Career Highlights
Hyun-Sook Jang is currently associated with Pharmabcine Inc., where he continues to advance his research in monoclonal antibodies. His work has garnered attention for its potential impact on cancer therapies and treatment methodologies.
Collaborations
Jang collaborates with notable colleagues, including Jin-San Yoo and Weon-Sup Lee, who contribute to his research endeavors. Their combined expertise enhances the innovative approaches taken in their projects.
Conclusion
Hyun-Sook Jang's contributions to the field of monoclonal antibody research are noteworthy. His innovative patents and collaborations position him as a key figure in the ongoing fight against cancer.